Hosseinion Warren's Form 4 filing
Veraxa Biotech AG · filed Sep 29, 2026
- Accession no.
- 0001829126-26-010557
- Filed
- Sep 29, 2026, 4:10 PM ET
- Trade date
- Sep 10, 2026
- Filing delay
- 19 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $10.1K. It was filed 19 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hosseinion WarrenCIK 0001438327 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | Ordinary Shares | PPurchaseAcquired | +6,024 | $1.67 | +$10,060.08 | 634,692 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.